Epidermal growth factor receptor tyrosine kinase inhibitors.

Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 1.85

Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference. J Pediatr (2006) 1.26

Growth factor-like activity of gliadin, an alimentary protein: implications for coeliac disease. Gut (2006) 1.12

Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World J Clin Oncol (2011) 1.06

Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol (2006) 1.05

Identification of novel growth factor-responsive genes in neuroendocrine gastrointestinal tumour cells. Br J Cancer (2005) 0.88

Anti-cancer Therapies in High Grade Gliomas. Curr Proteomics (2013) 0.86

PAR1 is selectively over expressed in high grade breast cancer patients: a cohort study. J Transl Med (2009) 0.85

Multistage carcinogenesis. Br J Cancer (2004) 0.84

Inhibition of autophosphorylation of epidermal growth factor receptor by small peptides in vitro. Br J Pharmacol (2006) 0.84

KIT, PDGFRalpha and EGFR analysis in nephroblastoma. Virchows Arch (2008) 0.82

EGFR tyrosine kinase targeted compounds: in vitro antitumor activity and molecular modeling studies of new benzothiazole and pyrimido[2,1-b]benzothiazole derivatives. EXCLI J (2014) 0.75

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol (2003) 15.10

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol (2004) 8.83

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol (2004) 8.15

Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res (2003) 6.43

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol (2002) 4.25

Severe acute interstitial pneumonia and gefitinib. Lancet (2003) 3.94

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol (2002) 3.53

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 3.32

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res (2001) 3.02

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2003) 2.85

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol (2003) 2.65

Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res (2003) 2.44

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res (2003) 2.26

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol (2002) 2.25

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol (2002) 2.25

Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J (1998) 2.04

Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res (2003) 1.82

ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res (2003) 1.80

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol (2003) 1.75

Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol (2003) 1.66

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res (2003) 1.35

The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol (2003) 1.32

Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res (2002) 1.23

CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol (2001) 1.13

Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin Cancer Res (2001) 1.03

Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study. Clin Cancer Res (2004) 1.01

Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann N Y Acad Sci (2002) 1.01

A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res (2003) 0.95

Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol (2003) 0.95

Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J (2003) 0.92

Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin Cancer Res (2001) 0.83

Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development. Semin Radiat Oncol (2002) 0.81

New directions for ZD1839 in the treatment of solid tumors. Semin Oncol (2003) 0.80

Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839. Int J Oncol (2003) 0.79

ZD1839 (Iressa): what's in it for the patient? Oncologist (2002) 0.78